Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             409 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 AJS-2 Bispecific and CAR T-cell immunotherapies for advanced prostate cancer Hawley, Jessica E.

34 S3 p. S1349
artikel
2 AJS-4 Current status and future challenges in clinical development of CAR-T cell therapy and bispecific antibody therapy for solid tumors Kitano, Shigehisa

34 S3 p. S1349
artikel
3 AJS-1 Navigating the expanding treatment landscape in R/R diffuse large B-cell lymphoma – how to incorporate CAR T-cell therapy and bispecific antibodies Nastoupil, Loretta J.

34 S3 p. S1349
artikel
4 Disclaimer
34 S3 p. iii
artikel
5 DJS-1 Regulatory challenges in the Asian clinical TriaLs network for cAancerS (ATLAS) project Nakamura, Kenichi

34 S3 p. S1350
artikel
6 DJS-4 Utilization of clinical research data other than conventional clinical trials for pharmaceuticals and medical devices Yamamoto, Haruko

34 S3 p. S1350
artikel
7 EC-3 Development of oncology fellowship between KSMO and KCSG in Korea: Current status of oncology education and framework for future oncology of KSMO Park, Yeon Hee

34 S3 p. S1375
artikel
8 EC-6 Educational initiative at Japanese Society of Medical Oncology (JSMO) Kinoshita, Ichiro

34 S3 p. S1375-S1376
artikel
9 EC-2 Oncology education initiatives at Chinese Society of Clinical Oncology (CSCO) Zhong, Jia

34 S3 p. S1375
artikel
10 EC-4 Oncology education initiatives at Singapore Society of Oncology (SSO) Ling Poon, Eileen Yi

34 S3 p. S1375
artikel
11 EC-5 Oncology education initiatives at Taiwan Oncology Society (TOS) Hsu, Chiun

34 S3 p. S1375
artikel
12 Editorial Board
34 S3 p. i
artikel
13 EJS-4 Development of molecularly-stratified precision medicine in lung cancer Matsumoto, Shingo

34 S3 p. S1351
artikel
14 EL06 Supportive care in cancer and adverse event management Naito, Tateaki

34 S3 p. S1374
artikel
15 GL04-3 Evidence for cancer vaccine therapy and immuno-cell therapy Shimoi, Tatsunori

34 S3 p. S1376
artikel
16 GL03-3 Venous thromboembolism in the era of oncocardiology Maruyama, Dai

34 S3 p. S1376
artikel
17 JS01-1 Aggregating comprehensive cancer genomic data and clinical information into C-CAT for utilization Ohkuma, Yusuke

34 S3 p. S1353
artikel
18 JS04-1 Clinical practice guidelines in cardio-oncology and the definition of cancer therapy-related cardiovascular toxicity Sase, Kazuhiro

34 S3 p. S1354
artikel
19 JS01-6 Imagine all the patients living life without recurrence Oki, Eiji

34 S3 p. S1353-S1354
artikel
20 JS01-4 Liquid biopsy-guided precision oncology in advanced solid tumors Nakamura, Yoshiaki

34 S3 p. S1353
artikel
21 JS01-3 Optimizing cancer genome medicine in clinical practice in Japan Muto, Manabu

34 S3 p. S1353
artikel
22 JS01-2 Toward efficient operation of expert panels Komine, Keigo

34 S3 p. S1353
artikel
23 JS01-5 Whole genome sequencing-based precision cancer medicine in Japan Kohno, Takashi

34 S3 p. S1353
artikel
24 ME05 Evolving landscape of systemic therapy for advanced hepatocellular carcinoma Kelley, Robin Kate

34 S3 p. S1377
artikel
25 ME13 Existing controvercies in bladder and kidney cancer Powles, Thomas

34 S3 p. S1378
artikel
26 ME11 How to overcome and circumvent acquired resistance to osimertinib or lazertinib in advanced EGFR mutant lung cancer? Cho, Byoung Chul

34 S3 p. S1378
artikel
27 ME10 Impact of the NETSARC network of reference centers for the diagnosis and treatment of sarcomas in France since 2010 Blay, Jean-Yves

34 S3 p. S1377-S1378
artikel
28 ME07 Management of women with advanced and recurrent gynecologic malignancies Tewari, Krishnansu Sujata

34 S3 p. S1377
artikel
29 ME01 New developments in B cell lymphoma Leonard, John P.

34 S3 p. S1377
artikel
30 ME04 Novel immunotherapy combinational approach in advanced oesophago-gastric adenocarcinoma Chau, Ian

34 S3 p. S1377
artikel
31 MO7-1 A Bayesian network meta-analysis comparing biliary stent types’ outcomes in unresectable malignant biliary obstruction Aryanti, Citra

34 S3 p. S1399
artikel
32 MO58-5 Abemaciclib-induced liver dysfunction in metastatic breast cancer Miyaki, Toshiko

34 S3 p. S1433
artikel
33 MO68-4 A chemoproteoinformatics approach demonstrates that aspirin increases sensitivity to MEK inhibition by directly binding to RPS5 Boku, Shogen

34 S3 p. S1438
artikel
34 MO34-4 Advanced hepatocellular carcinoma viral status and immunotherapy efficacy: A propensity-score matched analysis Low, Qin Jian

34 S3 p. S1417-S1418
artikel
35 MO4-4 Affecting burden and cost of care in caregiver of dependent advanced stage of cancer patients Chansriwong, Phichai

34 S3 p. S1397-S1398
artikel
36 MO15-6 A highly efficient procedure for the recovery of DNA from formalin-fixed paraffin-embedded tissue sections Oba, Utako

34 S3 p. S1406
artikel
37 MO2-7 A multicenter prospective observational study of pre-existing autoantibodies in patients with small-cell lung cancer treated with ICI Hata, Akito

34 S3 p. S1396
artikel
38 MO39-5 Analysis of perioperative chemotherapy-mediated genomic changes in gastric cancer Ikegame, Ko

34 S3 p. S1421-S1422
artikel
39 MO42-6 Analysis of sperm preservation in patients with mediastinal germ cell tumor patients Umamoto, Kotaro

34 S3 p. S1423-S1424
artikel
40 MO57-1 A phase II study of chemotherapy plus local therapy for non-small cell lung cancer with oligometastases: TORG1529 Saito, Go

34 S3 p. S1431-S1432
artikel
41 MO31-5 A project to investigate the actual status of biomarker testing in unresectable advanced or recurrent non-small cell lung cancer: WJOG15421 L (REVEAL) Kawashima, Yosuke

34 S3 p. S1416
artikel
42 MO46-1 A retrospective study on the development of osteonecrosis of the jaws (ONJ) in patients treated with bone modifying agents (BMA) Yamanaka, Taro

34 S3 p. S1425
artikel
43 MO54-5 Assessment of the impact of COVID-19 on malignancy surgeries by interrupted time series analysis using real world data Nio, Mariko

34 S3 p. S1430
artikel
44 MO31-3 Association between tumor mutation burden and oncogenic mutation affecting the immune system of patients with non-small cell lung cancer Kobayashi, Takayuki

34 S3 p. S1416
artikel
45 MO57-4 Association of Glasgow prognostic score with efficacy and safety of first-line osimertinib in EGFR mutated NSCLC (OSI-FACT exploratory analysis) Oya, Yuko

34 S3 p. S1432
artikel
46 MO58-3 A study of palbociclib-resistant cases at our hospital-discussion on abemaciclib treatment feasibility Noguchi, Eiichiro

34 S3 p. S1433
artikel
47 MO34-3 A systematic review of the effect of statin use on risk of hepatocellular carcinoma Mandaring, Putri Patricia

34 S3 p. S1417
artikel
48 MO39-1 CapeOX therapy for elderly pts with advanced gastric cancer (phase II study with geriatric assessment, TCOG GI-1601) Muto, Osamu

34 S3 p. S1421
artikel
49 MO71-8 Carboplatin-based vs. cisplatin-based therapy for cervical cancer survival: A systematic review Kumar, Chandni

34 S3 p. S1440
artikel
50 MO58-4 CDK4/6 inhibitors as maintenance therapy after initial chemotherapy: A retrospective single-institute study Fujisawa, Fumie

34 S3 p. S1433
artikel
51 MO15-4 Challenges for lung cancer screening using blood samples – methylome analysis of plasma-derived cell-free DNA Nakagomi, Takahiro

34 S3 p. S1405
artikel
52 MO11-6 Characteristics of patients with pneumocystis pneumonia during cancer chemotherapy enrolled in the institutional serious adverse event database Tsujimura, Hideki

34 S3 p. S1403
artikel
53 MO13-4 Characterization of URST7 as a potential biomarker and therapeutic target for oral cancer Tsevegjav, Bayarbat

34 S3 p. S1404
artikel
54 MO72-5 Chemotherapy at home: Efficiency of anticipated treatment preparation Touil, Yacine

34 S3 p. S1441
artikel
55 MO21-5 Chemotherapy regimen of Kaposi sarcoma in HIV/AIDS patients: A systematic review of randomized controlled trials Kurniawan, Andree

34 S3 p. S1410
artikel
56 MO23-5 Choroid plexus tumors: A rare but formidable neurological malignancy Manjunath, Niveditha

34 S3 p. S1411
artikel
57 MO41-2 Circulating tumor DNA (ctDNA) predicts prognosis in triple-negative breast cancer patients: A systematic review Lokanata, Edellin F.

34 S3 p. S1422-S1423
artikel
58 MO48-2 Clinical adaptability of HSP90 inhibitor in refractory AML based on genetic mutation Ogata, Hiraku

34 S3 p. S1425
artikel
59 MO7-5 Clinical and genomic features of MSI-H and TMB-high pancreatic cancer: A real world data from the C-CAT database Sakakida, Tomoki

34 S3 p. S1400
artikel
60 MO6-1 Clinical characteristics and diagnostic process of NAFLD-associated HCC Ueno, Masayuki

34 S3 p. S1398
artikel
61 MO9-1 Clinical characteristics of HER2-low stage I triple-negative breast cancer Sanomachi, Tomomi

34 S3 p. S1401
artikel
62 MO10-2 Clinical decisions by the Molecular Tumor Board on comprehensive genomic profiling tests in Japan: A retrospective observational study Shirota, Hidekazu

34 S3 p. S1402
artikel
63 MO36-3 Clinical management of cancer of unknown primary with unfavorable subset: A retrospective analysis Tono, Yasutaka

34 S3 p. S1419
artikel
64 MO69-4 Clinical outcomes of everolimus for patients with advanced neuroendocrine tumors arising from the rectum: A single-institutional retrospective study Kim, Yuntae

34 S3 p. S1438
artikel
65 MO25-2 Clinical outcomes of systemic therapy for metastatic renal cell carcinoma patients on hemodialysis Iwasa, Shun

34 S3 p. S1412
artikel
66 MO25-4 Clinical outocomes of nivolumab plus ipilimumab in metastatic renal cell carinoma Kato, Taigo

34 S3 p. S1412
artikel
67 MO42-4 Clinical picture of thyroid cancer from the view of time to death from diagnosis Ito, Tokiko

34 S3 p. S1423
artikel
68 MO16-3 Clinical relevance of comprehensive genome profiling using real-world data in colorectal cancer Okugawa, Yoshinaga

34 S3 p. S1406
artikel
69 MO41-3 Clinical significance of oncogenic miRNAs (21,17,10a &10b) expression with breast cancer stem cells in breast carcinoma Dwivedi, Shailendra

34 S3 p. S1423
artikel
70 MO60-3 Clinical utility of gBRCA testing (BRACAnalysis) for patients with unresectable pancreatic cancer Kawamoto, Yasuharu

34 S3 p. S1434
artikel
71 MO49-2 CNS prophylaxis in diffuse large B-cell lymphoma: A meta-analysis and systematic review Arnejo Sy, Florge Francis

34 S3 p. S1426
artikel
72 MO9-4 Cognitive decline after receiving endocrine therapy and/or chemotherapy in breast cancer patients: A systematic review Tancherla, Angeline

34 S3 p. S1401-S1402
artikel
73 MO8-6 Comparision of the expression of p53 and survivin in fibroadenoma and invasive ductal carcinoma of the breast Banoria, Neeraj Kumar

34 S3 p. S1401
artikel
74 MO35-3 Comparison of clinical outcomes between 1st-line osimertinib, 1G/2G EGFR-TKIs followed by osimertinib and without osimertinib Uehara, Yuji

34 S3 p. S1418
artikel
75 MO5-5 Comparison of first-line therapy regimens for non-small cell lung cancer with different Japanese real world data sources Nio, Mariko

34 S3 p. S1398
artikel
76 MO57-6 Comprehensive genomic profiling is effective in determining treatment decisions for advanced solid tumors patients Ishida, Masaki

34 S3 p. S1432
artikel
77 MO69-5 Contribution of neuroendocrine differentiation to prognosis in extrapulmonary small cell or neuroendocrine carcinoma Takahashi, Nobuyuki

34 S3 p. S1438-S1439
artikel
78 MO13-2 Covalent FGFR inhibitor futibatinib exhibits sustained antitumor effects compared with ATP-competitive inhibitors Muraoka, Hiromi

34 S3 p. S1404
artikel
79 MO14-6 CT-based AI machine learning model for predicting efficacy of chemoradiotherapy for esophageal squamous cell carcinoma Kasai, Akinari

34 S3 p. S1405
artikel
80 MO72-1 Current status and problems of comprehensive cancer genome profiling test in biliary tract and pancreatic cancer in our institutions Okuyama, Hiroyuki

34 S3 p. S1441
artikel
81 MO40-4 DCF regimen might be useful as neo-adjuvant chemotherapy for esophageal cancer from our institutional experience Kobayashi, Kazuma

34 S3 p. S1422
artikel
82 MO15-3 Deep target sequencing of cytological tumor cells using whole genome amplification Amemiya, Kenji

34 S3 p. S1405
artikel
83 MO19-1 Definitive chemoradiation therapy with docetaxel, nedaplatin, and 5-fluorouracil (DNF-R) for locally advanced esophageal cancer – long-term follow-up Ohnuma, Hiroyuki

34 S3 p. S1407-S1408
artikel
84 MO7-6 Differences between tissue and blood specimens in CGP of pancreatic cancer from a real-world data of C-CAT Doi, Toshifumi

34 S3 p. S1400
artikel
85 MO58-2 Differences in treatment response to CDK4/6 inhibitors and endocrine therapy between HER2-negative and HER2-low expression groups Omori, Reo

34 S3 p. S1432-S1433
artikel
86 MO40-5 Early administration of pegfilgrastim contributes to the safety of DCF therapy as neoadjuvant chemotherapy for esophageal cancer Morita, Ryuichi

34 S3 p. S1422
artikel
87 MO2-5 Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer Takeuchi, Eiji

34 S3 p. S1395-S1396
artikel
88 MO28-5 Effectiveness of ketamine for depression among advanced cancer patients in palliative care: A systematic review Cipta, Darien Alfa

34 S3 p. S1414
artikel
89 MO61-3 Effect of cancer cachexia on the outcomes of first-line chemotherapy in pancreatic cancer: A claims database study Furuse, Junji

34 S3 p. S1435
artikel
90 MO18-2 Effects and risk factors of TAS-102 in real-world patients with metastatic colorectal cancer, EROTAS-R study Yoshida, Naohisa

34 S3 p. S1407
artikel
91 MO48-4 Efficacy and quality of life in blinatumomab treatment in patients with acute lymphoblastic leukemia: Systematic review Herijanto, Billie Edgara

34 S3 p. S1425
artikel
92 MO21-6 Efficacy and safety of chemotherapy in metastatic malignant phyllodes tumors Takigawa, Aya

34 S3 p. S1410-S1411
artikel
93 MO50-4 Efficacy and safety of commercially approved BCMA-targeting CAR-T therapy in triple-class refractory multiple myeloma Nishimura, Noriko

34 S3 p. S1427-S1428
artikel
94 MO46-2 Efficacy and safety of palliative radiation therapy for tumor bleeding in patients with advanced pancreatic cancer Shibuki, Taro

34 S3 p. S1425
artikel
95 MO59-2 Efficacy and safety of pembrolizumab plus chemotherapy in patient with metastatic TNBC: A systematic review Sabran, Mohammad Zuhriansyah

34 S3 p. S1434
artikel
96 MO49-5 Efficacy and safety of R-THP-COP therapy for elderly patients with untreated diffuse large B-cell lymphoma Kato, Daishi

34 S3 p. S1427
artikel
97 MO39-4 Efficacy and safety of trifluridine/tipiracil as a salvage-line treatment for patients with advanced gastric cancer Fukuda, Koshiro

34 S3 p. S1421
artikel
98 MO1-4 Efficacy of immune checkpoint inhibitors plus chemotherapy for TTF-1-negative non-squamous non-small cell lung cancer Iso, Hirokazu

34 S3 p. S1394
artikel
99 MO61-6 Efficacy of third-line chemotherapy after liposomal irinotecan and fluorouracil with folinic acid for pancreatic cancer Kawasaki, Reina

34 S3 p. S1435
artikel
100 MO56-2 Efficacy of whole brain radiotherapy for patients with leptomeningeal metastasis of non-small cell lung cancer: NEJ049 Furuta, Megumi

34 S3 p. S1431
artikel
101 MO38-3 EGFR activation elicited adaptive resistance to lorlatinib in ALK-rearranged non-small cell lung cancer cells Katayama, Yuki

34 S3 p. S1421
artikel
102 MO52-6 Estimating suicide incidence over time in cancer patients in the early period following cancer diagnosis Watanabe, Kaname

34 S3 p. S1429
artikel
103 MO58-6 Evaluation of cardiotoxicity by anti-HER2 therapy Itagaki, Tomoko

34 S3 p. S1433-S1434
artikel
104 MO62-4 Evaluation of the significance of subcarinal lymph node dissection in stage IB non-small cell lung cancer Wang, Feng

34 S3 p. S1435-S1436
artikel
105 MO52-4 Examination of patient characteristics in breast cancer patients who underwent BRCA genetic testing, according to reason for taking the test Sakakibara, Ayaka

34 S3 p. S1428-S1429
artikel
106 MO71-7 Extensive analysis of machine learning algorithms in predicting the treatment outcome of HIFU ablation of adenomyosis Akpinar, Emine

34 S3 p. S1440
artikel
107 MO36-6 Factors related to family caregiver-perceived burden associated with testing and diagnosis of cancer of unknown primary Ishida, Kyoko

34 S3 p. S1420
artikel
108 MO28-6 Feasibility of the online-based QOL survey in patients with head and neck cancer. A multi-center, prospective study Ishiki, Hiroto

34 S3 p. S1414
artikel
109 MO20-5 Five-year survival rate of AYA patients from sarcoma: A prospective fixed cohort study in Bangladesh Al Mamun Khan, Abdullah

34 S3 p. S1409
artikel
110 MO12-2 G-CVP therapy using obinutuzumab for follicular lymphoma Yamada, Toshiki

34 S3 p. S1404
artikel
111 MO10-5 Germline and somatic whole exome sequencing identifies a novel candidate gene in double primary BCRA-associated cancers Tanioka, Maki

34 S3 p. S1402-S1403
artikel
112 MO29-2 Health literacy in adolescents and young adult oncology: A review on measurement tools Tian Woon, Brian Shao

34 S3 p. S1415
artikel
113 MO72-6 Health-related quality of life in different states of Thai patients with breast cancer – preliminary report Luangdilok, Sutima

34 S3 p. S1441-S1442
artikel
114 MO21-2 High incidence of cancer therapeutics-related cardiac dysfunction in the patients with cardiac sarcoma Uehara, Koki

34 S3 p. S1410
artikel
115 MO65-2 High intramuscular adipose tissue content is a favorable prognostic factor in patients with advanced gastric cancer treated with nivolumab Tanaka, Toshimitsu

34 S3 p. S1436
artikel
116 MO16-5 Identification and evaluation of a serum microRNA panel for screening advanced colorectal polyps Ng, Lui

34 S3 p. S1406
artikel
117 MO13-5 Identification of URST1 as a biomarker and therapeutic target for lung cancer Takano, Atsushi

34 S3 p. S1405
artikel
118 MO7-4 Impact of biliary drainage for pancreatic cancer treated with nanoliposomal irinotecan, fluorouracil and folinic acid Nishikawa, Kazuo

34 S3 p. S1400
artikel
119 MO51-2 Impact of COVID-19 on cancer care in India: A multi-institutional experience Behera, Manoj Kumar

34 S3 p. S1428
artikel
120 MO51-6 Impact of COVID-19 pandemic on the diagnosis of cancers – a systematic review Tik, Cheung Ka

34 S3 p. S1428
artikel
121 MO19-4 Impact of tislelizumab on health-related quality of life in Asian patients with esophageal squamous cell carcinoma Kato, Ken

34 S3 p. S1408
artikel
122 MO55-5 Impact of tumor genomic alterations on development of cancer cachexia in patients with advanced non-small cell lung cancer Fujii, Hiroyuki

34 S3 p. S1430
artikel
123 MO56-3 Incidence of synchronous or metachronous multiple cancers and their predictive factors in patients with non-small cell lung cancer Honda, Takeshi

34 S3 p. S1431
artikel
124 MO3-2 Influence of durvalumab consolidation on pneumonitis after chemoradiotherapy for unresectable non-small cell lung cancer Murata, Saori

34 S3 p. S1396
artikel
125 MO45-4 Integrated learning of palliative care and oncology is useful for nursing patients with intractable cancer Nakamura, Masako

34 S3 p. S1424-S1425
artikel
126 MO59-6 Karyopherin alpha 2 (KPNA2) predicts prognosis in breast cancer patients: A systematic review and meta-analysis Lokanata, Michael G.

34 S3 p. S1434
artikel
127 MO54-1 Kynurenine-to-tryptophan ratio in solid cancer patients receiving ChAdOx1-nCoV-19 vaccine Panasawatwong, Bunnatut

34 S3 p. S1429-S1430
artikel
128 MO1-1 LIGHT-NING 2nd interim analysis: Early safety of 1L nivolumab + ipilimumab +/- chemotherapy for NSCLC in Japan Azuma, Koichi

34 S3 p. S1393
artikel
129 MO29-5 Location of death of adolescents and young adults with cancer Yamada, Yoko

34 S3 p. S1415
artikel
130 MO35-5 Long-term efficacy and safety from the CROWN study in Japanese patients with ALK+ advanced non-small cell lung cancer Teraoka, Shunsuke

34 S3 p. S1418
artikel
131 MO32-5 Metabolic interaction between gut microbiome and PIK3CA-mutated colorectal cancer: SCRUM-Japan MONSTAR-SCREEN Boku, Shogen

34 S3 p. S1416
artikel
132 MO21-1 MRI radiomics to predict recurrence and prognosis in patients with soft-tissue sarcoma Cheung, Eva Y.W.

34 S3 p. S1409
artikel
133 MO2-4 Multicenter pharmacokinetic study of pembrolizumab for non-small cell lung cancer in older adults aged over 75 years Saeki, Sho

34 S3 p. S1395
artikel
134 MO66-6 Multicenter prospective observational study on treatment and prognosis of patients with primary small bowel cancer Yamashita, Haruhiro

34 S3 p. S1437
artikel
135 MO17-2 Multicenter retrospective study of vulnerable patients with metastatic colorectal cancer: Results of second-line therapy Kawakami, Kentaro

34 S3 p. S1406-S1407
artikel
136 MO57-5 Multicenter retrospective study to evaluate necitumumab plus CDDP/GEM after ICIs in advanced squamous-cell lung cancer in Japan (NINJA study) Tanzawa, Shigeru

34 S3 p. S1432
artikel
137 MO20-6 Multidisciplinary treatment for retrospective sarcoma in Japan Iwata, Shintaro

34 S3 p. S1409
artikel
138 MO26-1 Needs for cancer information in patients with rare cancers: Analysis of the questionnaire from the participants in “Meet the Expert on Rare Cancer” Katoh, Yoko

34 S3 p. S1413
artikel
139 MO7-3 Network meta-analysis of first-line therapy for unresectable, advanced or recurrent biliary tract cancer Kikuchi, Yoshinori

34 S3 p. S1399
artikel
140 MO63-3 Nivolumab monotherapy in second- or later-line treatment for advanced or recurrent esophageal cancer Miyajima, Saori

34 S3 p. S1436
artikel
141 MO36-5 Non-familial prospective risk factors in predicting cancer of unknown primary: A systematic review and meta-analysis Sembiring, Stephani Clarissa

34 S3 p. S1420
artikel
142 MO49-4 Obinutuzumab and reduced bendamustine for elderly follicular lymphoma patients: A single institution retrospective study Masamoto, Yosuke

34 S3 p. S1426-S1427
artikel
143 MO5-4 Off-label or unapproved drug use and physicians' expectations of life insurance companies Higuchi, Yukiko

34 S3 p. S1398
artikel
144 MO24-6 Olfactory system of canines to identify prostate cancer by urine-based detection: A systematic review and meta-analysis Firsty, Naufal Nandita

34 S3 p. S1412
artikel
145 MO72-2 Oncofix – an oncology software prepared by Oncologist Pathak, Abhishek

34 S3 p. S1441
artikel
146 MO44-4 Outcome for recurrent nasopharyngeal carcinoma in Malaysia: University Malaya Medical Centre, 2010-2019 Abdul Satar, Nur Fadhlina

34 S3 p. S1424
artikel
147 MO20-3 Outcome of parameningeal head and neck rhabdomyosarcoma in adults: Kyushu Medical Oncology Group Study Isobe, Taichi

34 S3 p. S1409
artikel
148 MO63-2 Overall survival for esophageal cancer patients with pembrolizumab: Systematic review Sutanto, Mario

34 S3 p. S1436
artikel
149 MO69-3 Pathological predictors of the response to platinum-based chemotherapy in pancreatobiliary neuroendocrine carcinoma Furukawa, Takaaki

34 S3 p. S1438
artikel
150 MO70-2 Pegfilgrastim with second-line amrubicin for relapsed small cell lung cancer: Single institution experience Shibata, Kazuhiko

34 S3 p. S1439
artikel
151 MO71-5 Pembrolizumab effectiveness in platinum-resistant ovarian carcinoma: Systematic review Law, Natasha Karlina

34 S3 p. S1440
artikel
152 MO11-1 Phase I dose-finding study of the SIRPα inhibitor BI 765063 as monotherapy in Japanese patients with advanced cancer Doi, Toshihiko

34 S3 p. S1403
artikel
153 MO3-3 Phase II study of S-1+CDDP with concurrent TRT followed by durvalumab for unresectable LA-NSCLC in Japan (SAMURAI) Tanzawa, Shigeru

34 S3 p. S1396
artikel
154 MO4-2 Phase 1 study of ABBV-400, a novel anti-Met antibody drug conjugate, in advanced solid tumors Shimizu, Toshio

34 S3 p. S1397
artikel
155 MO38-1 Phase 1 study of ABBV-155 ± paclitaxel in relapsed/refractory solid tumors: Results in Japanese patients Shimizu, Toshio

34 S3 p. S1420
artikel
156 MO50-5 Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma Izutsu, Koji

34 S3 p. S1428
artikel
157 MO21-4 Platelet-lymphocyte ratio as prognostic factor in soft tissue sarcoma Chandra, Amos Immanuel

34 S3 p. S1410
artikel
158 MO8-5 Pneumocystis jiroveci pneumonia in patients receiving ddAC for breast cancer: A single center retrospective study Manako, Chika

34 S3 p. S1400-S1401
artikel
159 MO2-2 Post-marketing observational safety study of durvalumab in Japanese patients with unresectable stage III NSCLC (PACIFIC regimen) Kato, Terufumi

34 S3 p. S1395
artikel
160 MO38-2 Post-marketing surveillance of tepotinib for non-small cell lung cancer with MET exon 14 skipping mutations – final report Kato, Terufumi

34 S3 p. S1420-S1421
artikel
161 MO62-1 Prediction of early lung cancer development using whole lung texture analysis from LDCT Huang, Wei-Ming

34 S3 p. S1435
artikel
162 MO72-3 Predictive factors of post-operative acute kidney injury after CRS-HIPEC in patients with peritoneal carcinomatosis Cabiling, Chito Clarin

34 S3 p. S1441
artikel
163 MO18-6 Predictive value of CDC37 gene expression for regorafenib in metastatic colorectal cancer (mCRC) Arai, Hiroyuki

34 S3 p. S1407
artikel
164 MO50-3 Preliminary data from the phase I/II study of TP-3654, an oral PIM-1 kinase inhibitor, in patients with myelofibrosis El Chaer, Firas

34 S3 p. S1427
artikel
165 MO52-5 Prevalence and clinical features of triple-negative breast cancer in a tertiary government hospital in the Philippines Maano, Omar Paningbatan

34 S3 p. S1429
artikel
166 MO23-3 Primary bony tumors of cranio-cervical junction and upper cervical spine: Management and their outcome from 21 cases Kumarasamy, Sivaraman

34 S3 p. S1411
artikel
167 MO62-7 Prognostic evaluation using cfDNA in patients with resectable lung cancer Murase, Yuya

34 S3 p. S1436
artikel
168 MO35-1 Prognostic evolution of EGFR-mutated non-small cell lung cancer over the past 20 years since the beginning with gefitinib Nakagomi, Takahiro

34 S3 p. S1418
artikel
169 MO55-4 Prognostic impact and predictive biomarkers of immune checkpoint inhibitor-induced interstitial lung disease for non-small cell lung cancer Murata, Daiki

34 S3 p. S1430
artikel
170 MO36-4 Prognostic impact of genetic mutations in unfavorable cancer of unknown primary site Tang, Chengyu

34 S3 p. S1419
artikel
171 MO48-5 Progression of disease within 5 months of adult T-cell leukemia-lymphoma (ATL5) as a clinical endpoint for high-risk mortality outcomes Sano, Haruhiko

34 S3 p. S1426
artikel
172 MO35-6 Prospective exosome-focused translational research for afatinib study of non-small cell lung cancer patients expressing EGFR (EXTRA study) Morikawa, Kei

34 S3 p. S1418-S1419
artikel
173 MO23-6 Prospective study to evaluate the role of bevacizumab in treatment of vestibular schwannoma in neurofibromatosis type 2 V, Pavana

34 S3 p. S1411-S1412
artikel
174 MO9-5 Psychological interventions for managing depression among post intervention breast cancer patients: A systematic review Dharmaraja, Fernando

34 S3 p. S1402
artikel
175 MO27-1 Psychosocial risk factors of chronic pain among post-surgical breast cancer survivors: A systematic review Wijovi, Felix

34 S3 p. S1413
artikel
176 MO3-4 Radiotherapy technique recommendation based on radiomics for non-small cell lung cancer (NSCLC) patients Cheung, Eva Y.W.

34 S3 p. S1397
artikel
177 MO56-1 Randomized phase II study of zoledronate dosing every 4 versus 8 weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312) Tamiya, Motohiro

34 S3 p. S1431
artikel
178 MO18-4 RAS status in ctDNA and efficacy of FOLFIRI plus ramucirumab in 2nd-line therapy for RAS wild-type mCRC: JACCRO CC-16AR Sunakawa, Yu

34 S3 p. S1407
artikel
179 MO1-3 Real-world data of first-line treatment with pembrolizumab for NSCLC with high PD-L1 expression (HOT/NJLCG2001 secondary report) Tateishi, Kazunari

34 S3 p. S1394
artikel
180 MO34-1 Real-world evidence of precision medicine for biliary tract cancer Hayashi, Hideyuki

34 S3 p. S1417
artikel
181 MO71-4 Real-world treatment of niraparib as maintenance therapy in patients newly diagnosed advanced ovarian cancer in Japan Shimada, Muneaki

34 S3 p. S1440
artikel
182 MO6-2 Regorafenib plus tislelizumab as first-line systemic therapy for patients with advanced hepatocellular carcinoma (HCC) Chuang, Chienhuai

34 S3 p. S1398
artikel
183 MO33-2 Retrospective analysis of urothelial carcinoma treated with enfortumab vedotin at our institution Imai, Toru

34 S3 p. S1417
artikel
184 MO66-4 Retrospective study of gastric cancer with myelocarcinomatosis: A novel aspect of treatment for disseminated intravascular coagulation Kusano, Wataru

34 S3 p. S1437
artikel
185 MO1-5 Role of immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients <40 years old of age Takamori, Shinkichi

34 S3 p. S1394
artikel
186 MO28-1 Self-care towards the end of life: A systematic review and narrative synthesis on access, quality and cost Gallagher, Joshua

34 S3 p. S1413
artikel
187 MO28-4 Sleeplessness in breast cancer patients: A multicenter prospective observational study Aoki, Takuya

34 S3 p. S1414
artikel
188 MO11-4 Stereotactic body radiotherapy (SBRT) for oligometastases: Real-world outcome in multi-ethnic Asian patients Mohamad, Noor Nabila

34 S3 p. S1403
artikel
189 MO1-6 Steroid-resistant and refractory irAEs requiring additional immunosuppressants to steroids in advanced NSCLC patients Shimoda, Yukiko

34 S3 p. S1394-S1395
artikel
190 MO19-3 Subgroup analyses of phase II study of weekly paclitaxel in advanced esophageal cancer that had previously received docetaxel-containing chemotherapy Nakashima, Koji

34 S3 p. S1408
artikel
191 MO1-2 Subgroup analysis of atezo + bev + carbo + pac for previously treated patients with EGFRm NSCLC (NEJ043) Shiihara, Jun

34 S3 p. S1393
artikel
192 MO71-1 Systematic quantification of ovarian tumour heterogeneity using an in silico tissue microarray approach Reinius, Marika

34 S3 p. S1439-S1440
artikel
193 MO49-7 The clinical impact of chronic hepatitis C infection on hematologic malignancies: A systematic review Lin, Wan-Shiuan

34 S3 p. S1427
artikel
194 MO70-5 The clinical outcomes for anamorelin in advanced gastrointestinal cancer patients with cancer cachexia Nishimura, Ari

34 S3 p. S1439
artikel
195 MO32-6 The development of an expert panel support program using the Python programming language Yamaguchi, Tatsuro

34 S3 p. S1416-S1417
artikel
196 MO49-1 The efficacy of high-dose versus intrathecal methotrexate for DLBCL with high risk of CNS relapse: A multicenter retrospective study Akimoto, Masahiro

34 S3 p. S1426
artikel
197 MO3-6 The elderly subgroup analysis in real world survey (CRIMSON) of concurrent chemoradiotherapy in locally advanced NSCLC Tamiya, Akihiro

34 S3 p. S1397
artikel
198 MO54-4 The impact and development of the shared decision-making in cancer treatment during the COVID-19 pandemic Lin, Wan-Shiuan

34 S3 p. S1430
artikel
199 MO26-4 The impact and emerging issues of confirmation of chemotherapy regimen by a pharmacist in our breast oncology Ozeki, Rie

34 S3 p. S1413
artikel
200 MO40-3 The impact of sarcopenia on adverse events during neoadjuvant chemotherapy in esophageal squamous cell carcinoma Tsuji, Takayuki

34 S3 p. S1422
artikel
201 MO25-1 The impact of sarcopenia on survival and chemotoxicity in metastatic renal cell carcinoma patients: A meta-analysis Tancherla, Angeline

34 S3 p. S1412
artikel
202 MO22-3 The outcomes of glioblastoma multiforme: The University Malaya Medical Centre experience 2008-2018 Fa'Izah Ab Muin, Nur

34 S3 p. S1411
artikel
203 MO69-6 The possibility of microtubule-related agents as a new treatment option for neuroendocrine carcinoma and small cell lung cancer Yamaga, Satoru

34 S3 p. S1439
artikel
204 MO29-1 The present activity and issues of AYA support team for the patients in AYA generation Inagaki, Yuichiro

34 S3 p. S1414-S1415
artikel
205 MO43-1 The treatment sequence of weekly paclitaxel, carboplatin, and cetuximab (PCE) followed by nivolumab for R/M SCCHN Takeshita, Naohiro

34 S3 p. S1424
artikel
206 MO19-6 The use of ctDNA analysis in predicting esophageal cancer recurrence: A systematic review and meta-analysis D'Prinzessin, Celine Augla

34 S3 p. S1408
artikel
207 MO66-2 The use of ramucirumab before nivolumab may improve survival for unresectable advanced or recurrent gastric cancer Hirata, Shoichiro

34 S3 p. S1437
artikel
208 MO29-3 Transition of childhood cancer survivors to adult care – what we have learned from the experience of Cancer Survivorship Clinic over the past 3 years Taniyama, Tomoko

34 S3 p. S1415
artikel
209 MO41-6 Trastuzumab-deruxtecan and blood inflammatory markers in HER2-positive metastatic breast cancer Onishi, Mai

34 S3 p. S1423
artikel
210 MO6-6 Treatment effect of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma aiming at curative conversion therapy Tomonari, Tetsu

34 S3 p. S1399
artikel
211 MO53-3 Treatment for older patients with genitourinary cancer at Kyushu Cancer Center Negishi, Takahito

34 S3 p. S1429
artikel
212 MO12-1 Treatment patterns and outcomes in CLL/SLL after BTK inhibitor exposure using a Japanese claims database Kusumoto, Shigeru

34 S3 p. S1403-S1404
artikel
213 MO9-3 Triple-negative and hormone-positive breast cancer: The association with reproductive factors among Bangladeshi women Islam, Muhammad Rafiqul

34 S3 p. S1401
artikel
214 MO60-4 Tryptophan is the prognostic factor in patients with unresectable pancreatic cancer Saito, Kei

34 S3 p. S1434
artikel
215 MO12-3 Tumor-associated macrophage as prognostic indicator in patients with non-Hodgkin’s lymphoma: A systematic review Liem, Jean Andrina

34 S3 p. S1404
artikel
216 MO6-5 Tumor microenvironment and clinical efficacy of atezolizumab plus bevacizumab for hepatocellular carcinoma Taira, Tomonao

34 S3 p. S1399
artikel
217 MO36-2 Updated analysis from a phase II study on the efficacy of nivolumab in patients with cancer of unknown primary (NivoCUP) Funakoshi, Yohei

34 S3 p. S1419
artikel
218 MO45-2 Usefulness of urine dipstick test in the management of adverse events associated with immune checkpoint inhibitors Izumi, Keishiro

34 S3 p. S1424
artikel
219 MO30-1 Validation of a prediction tool for chemotherapy toxicity in older adults with cancer in Ramathibodi Hospital, Thailand Liengudom, Chaninart

34 S3 p. S1415
artikel
220 O1-1 A comparative study of TMB values in comprehensive genomic profiling assays in different gene panels Nishino, Takahiro

34 S3 p. S1383
artikel
221 O2-2 A comparative study on awareness of cervical cancer among female patients in urban and rural areas of Bangladesh Sultana, Farzana

34 S3 p. S1383-S1384
artikel
222 O4-3 An update analysis of the JACCRO CC-16: Ramucirumab plus FOLFIRI for RAS wild-type mCRC refractory to anti-EGFR antibody Manaka, Dai

34 S3 p. S1385
artikel
223 O7-2 A phase II study to assess the efficacy of osimertinib in patients with EGFR MT(+)T790M(-) NSCLC Hayakawa, Daisuke

34 S3 p. S1387
artikel
224 O17-2 A phase II trial of tazemetostat for patients with unresectable or metastatic epithelioid sarcoma (TAZETTA trial) Kita, Shosuke

34 S3 p. S1392
artikel
225 O16-4 A phase 2 trial of nivolumab monotherapy in rare cancer patients with mismatch repair deficiency or MSI-high: ROCK trial (NCCH1709) from MASTER KEY Project Tsuchihashi, Kenji

34 S3 p. S1391
artikel
226 O14-1 A randomized phase II study comparing S-1 plus oxaliplatin with S-1 monotherapy for elderly patients with advanced gastric cancer: WJOG8315G Makiyama, Akitaka

34 S3 p. S1390
artikel
227 O10-3 Association between necitumumab skin toxicity and efficacy in squamous NSCLC: A pooled analysis from SQUIRE and JFCM Yoshioka, Hiroshige

34 S3 p. S1388-S1389
artikel
228 O2-3 Cervical cancer risk factor classifying using data mining and machine learning approach to early diagnosis and treatment Islam, Md Shariful

34 S3 p. S1384
artikel
229 O4-5 Circulating tumor DNA dynamics as an early predictor of recurrence in patients with radically resected colorectal cancer: GALAXY study in the CIRCULATE-Japan Mishima, Saori

34 S3 p. S1385
artikel
230 O6-4 Clinicoimmunological study of sarcomatoid carcinoma across organs Morisue, Ryo

34 S3 p. S1386
artikel
231 O5-3 Expert training workshop on support for balancing cancer treatment and work organized by West Japan Oncology Group Ikeda, Satoshi

34 S3 p. S1386
artikel
232 O16-3 Extending adjuvant temozolomide may increase risk of adverse events while conferring no survival benefits in glioblastoma patients Kai Lau, Arthur Chak

34 S3 p. S1391
artikel
233 O3-1 Financial toxicity and cost-related experience in molecular and immune therapies: A multicenter questionnaire survey Yamamoto, Sena

34 S3 p. S1384
artikel
234 O6-3 Interim results of FIH phase 1 of TAK-102, GPC-3 targeted armored CAR-T therapy in patients with advanced solid tumors Kuboki, Yasutoshi

34 S3 p. S1386
artikel
235 O16-5 Nivolumab for cancer of unknown primary (CUP): Initial results from an expanded access program (NivoCUP2, WJOG14620M) Tanizaki, Junko

34 S3 p. S1392
artikel
236 O15-3 Nivolumab plus ipilimumab (N+I) for potentially resectable hepatocellular carcinoma (HCC): Efficacy and surgical outcome Su, Yung-Yeh

34 S3 p. S1390
artikel
237 O15-4 Outcomes of genetic aberrations and clinical features in cholangiocarcinoma: Report from the MASTER KEY Project Maruki, Yuta

34 S3 p. S1390
artikel
238 O9-1 Paclitaxel plus cetuximab vs. nivolumab for patients with platinum-refractory recurrent/metastatic head and neck cancer Kodama, Hiroyuki

34 S3 p. S1388
artikel
239 O7-4 Phase 1b efficacy of telisotuzumab vedotin and osimertinib in Asian vs non-Asian patients with advanced NSCLC Horinouchi, Hidehito

34 S3 p. S1387
artikel
240 O7-3 Phase II study of brigatinib in patients with TKI-naive ROS1-rearranged non-small cell lung cancer (NSCLC): Barossa study Takahashi, Toshiaki

34 S3 p. S1387
artikel
241 O16-2 Phase I trial of NY-ESO-1 TCR-T cell therapy combined with nanoparticulate vaccine but without lymphodepletion for STS Ishihara, Mikiya

34 S3 p. S1391
artikel
242 O1-2 Prospective study of comprehensive genomic profiling for chemotherapy-naive cancer patients (FIRST-Dx study) Ebi, Hiromichi

34 S3 p. S1383
artikel
243 O2-5 Quality of sex in cervical cancer survivors post-treatment: A systematic review Angel, Patricia

34 S3 p. S1384
artikel
244 O8-1 Real-world anamorelin use in 4,672 patients with cancer cachexia; Results from post-marketing all-case surveillance Muro, Kei

34 S3 p. S1387-S1388
artikel
245 O13-5 Rejuvenated BCMA-specific CD8αβ+ memory T cells to treat multiple myeloma using induced pluripotent stem cell technology Bae, Jooeun

34 S3 p. S1389-S1390
artikel
246 O5-1 Reliability and validity of the Japanese version of the Chemotherapy-induced Alopecia Distress Scale Aoyama, Yosuke

34 S3 p. S1385-S1386
artikel
247 O9-2 Salvage chemotherapy with paclitaxel plus cetuximab (PE)-based regimen following immune checkpoint inhibitor in R/M SCCHN Tanaka, Hideki

34 S3 p. S1388
artikel
248 O1-3 Selection bias due to left-truncation in comprehensive genomic profiling test and differences between Japan and the United States Ikegami, Masachika

34 S3 p. S1383
artikel
249 O13-3 Subcutaneous epcoritamab in Japanese patients with relapsed/refractory diffuse large B-cell lymphoma: EPCORE NHL-3 data Izutsu, Koji

34 S3 p. S1389
artikel
250 O10-2 Telisotuzumab vedotin monotherapy in Asian patients with c-Met–overexpressing advanced non-small cell lung cancer Horinouchi, Hidehito

34 S3 p. S1388
artikel
251 O3-4 Umbrella reviews of systematic reviews assessing pelvic floor muscle training on post-radical prostatectomy incontinence Lin, Wan-Shiuan

34 S3 p. S1384-S1385
artikel
252 O13-4 2-year update of KTE-X19 in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) in ZUMA-3 Shah, Bijal D.

34 S3 p. S1389
artikel
253 P43-3 A case of complete response to entrectinib in NTRK fusion gene-positive parotid carcinoma Moriyama, Etsuko

34 S3 p. S1457-S1458
artikel
254 P21-7 A case of male breast cancer with long-term disease control with fulvestrant + abemaciclib Takahashi, Miyuki

34 S3 p. S1449-S1450
artikel
255 P53-2 A case of metastatic prostate cancer mimicking malignant lymphoma Itagaki, Nae

34 S3 p. S1460
artikel
256 P19-10 A case of non-invasive therapy for unresectable desmoid fibromatosis with perforation of the gastrointestinal tract Miyake, Hiroaki

34 S3 p. S1448
artikel
257 P45-5 A case report of pneumothorax after treatment with bevacizumab-containing chemotherapy for metastatic breast cancer Suzuki, Hitomi

34 S3 p. S1459
artikel
258 P57-5 A case report of primary unresectable hilar cholangiocarcinoma eventually causing colonic obstruction due to peritoneal dissemination after chemoradiation Toyofuku, Atsushi

34 S3 p. S1462-S1463
artikel
259 P19-9 Acinar cell carcinoma of the pancreas: A case report Kamolrat, Nuttawut

34 S3 p. S1448
artikel
260 P29-10 Actionable genomic alterations in Filipino cancer patients using next-generation sequencing (NGS) liquid biopsy test Cruz Ordinario, Mel Valerie

34 S3 p. S1452-S1453
artikel
261 P25-10 Advanced NSCLC patients: Comparison between those with and without brain metastases Techasatian, Tanwimon

34 S3 p. S1451
artikel
262 P40-7 Anal neuroendocrine carcinoma masquerading external hemorrhoid: Case report of a rare and aggressive malignancy Sookthon, Chatsuda

34 S3 p. S1457
artikel
263 P10-1 Analysis of thromboembolism and prognosis in metastatic pancreatic cancer: A secondary analysis of Tokushukai REAl-world Data project 03-S1 Shimoyama, Rai

34 S3 p. S1445
artikel
264 P19-7 An asymptomatic steroid cell tumor of ovary – A rare case report Zaid, Rizma Mohd

34 S3 p. S1448
artikel
265 P32-8 An inter-facility linkage case for palliative care and cancer pharmacotherapy in the Kagawa Medical Information Network Murakami, Akitsu

34 S3 p. S1454
artikel
266 P63-3 A pivotal role of interdisciplinary team medicine in lenvatinib plus pembrolizumab therapy against advanced endometrial cancer Sonoda, Kenzo

34 S3 p. S1463
artikel
267 P58-8 A rare case of bleomycin-induced severe skin reactions: A case reports and literature review Ariful Islam, Syed Mohammad

34 S3 p. S1463
artikel
268 P66-5 A rare case of phylloides tumor of overt treatment with radiotherapy of a female breast cancer patient in Bangladesh Islam, Noorjahan

34 S3 p. S1465
artikel
269 P31-9 A retrospective study of elderly and non-elderly patients with metastatic pancreatic cancer treated with GEM+nab-PTX therapy Kawamoto, Yasuyuki

34 S3 p. S1453
artikel
270 P22-2 A single center treatment experience of combination with chemotherapy and nivolumab for HER2-negative gastric cancer Tsugaru, Kai

34 S3 p. S1450
artikel
271 P54-3 AS101 inhibits tumor metastasis by down-regulation of heparanase Wenjun, Fan

34 S3 p. S1461
artikel
272 P29-8 A study of lung cancer cases who participated in cancer genome medicine at our hospital Sumii, Masahiko

34 S3 p. S1452
artikel
273 P44-1 A study of 11 patients treated with trastuzumab deruxtecan including those with interstitial lung disease Higuchi, Toru

34 S3 p. S1458-S1459
artikel
274 P65-3 Attitudes and job demand among nurses toward medical oncology clinical trials: Exploration of the component factors Osawa, Shino

34 S3 p. S1465
artikel
275 P13-5 Autologous transplantation with thiotepa and busulfan for primary neurolymphomatosis with CNS involvement Araie, Hiroaki

34 S3 p. S1447
artikel
276 P55-2 BRCA2 reversion mutations as a resistance mechanism of olaparib in patients with BRCA2-associated mCRPC Takemura, Kohji

34 S3 p. S1461-S1462
artikel
277 P8-5 Calculation of medical personnel expenses to conduct a comprehensive genomic profiling test in Japan Kage, Hidenori

34 S3 p. S1445
artikel
278 P43-5 Case report: Clear cell carcinoma of urethra Tuitemwong, Pimchanok

34 S3 p. S1458
artikel
279 P27-5 Case report: Efficacy of platinum in metastatic castration-resistant prostate cancer (mCRPC) with BRCA2 mutation Palanupap, Kanokrat

34 S3 p. S1451
artikel
280 P63-5 Cases of atypical femur fractures; the rare adverse events requiring the multidisciplinary team decision-making Kanehira, Dan

34 S3 p. S1464
artikel
281 P20-3 CDK1 expression in breast cancer Lim, Yueh Ni

34 S3 p. S1449
artikel
282 P18-7 Chemotherapy for advanced urachal carcinoma: A case series of three patients Kitazono, Takafumi

34 S3 p. S1448
artikel
283 P26-9 Clinical outcome of nivolumab and ipilimumab in untreated advanced non-small cell lung cancer patients Sugimoto, Akira

34 S3 p. S1451
artikel
284 P30-1 Comparison of efficacy of atezolizumab and bevacizumab treatment for hepatocellular carcinoma between tyrosine kinase inhibitor-naive and -experienced patients Nishijima, Norihiro

34 S3 p. S1453
artikel
285 P65-1 Development of genome data repository system for big data utilization and secure storage Amano, Toraji

34 S3 p. S1464
artikel
286 P3-5 DLBCL developed during the immune checkpoint inhibitor therapy in a patient with advanced gastric cancer Takamizawa, Shigemasa

34 S3 p. S1443
artikel
287 P64-2 Durable response and adverse events in a patient with non-MSI-H uterine clear cell carcinoma on pembrolizumab/lenvatinib Chan, Jack Junjie

34 S3 p. S1464
artikel
288 P9-2 Effect of Ayurveda based CAM therapy on quality of life in elderly patient with hepatic cell carcinoma Bendale, Yogesh

34 S3 p. S1466
artikel
289 P11-4 Efficacy and safety of anti-CD38 antibodies in combination with pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma Sato, Tsuyoshi

34 S3 p. S1446
artikel
290 P50-5 Efficacy and safety of CBDCA/ETP/ICI combination therapy for extensive-stage small cell lung cancer in elderly patients Fukasawa, Naoto

34 S3 p. S1460
artikel
291 P12-3 Eficacy and mortality of venetoclax as promising treatment for acute myeloid leukemia: Systematic review Kosayuz, Sherina

34 S3 p. S1446-S1447
artikel
292 P28-6 Evaluation of PDT efficacy by an intense pulsed laser in breast cancer spheroids in simulated hormonal microenvironment Chu, Ellie Sm

34 S3 p. S1452
artikel
293 P56-11 Evaluation of the nematode C. elegans cancer test (N-NOSE) in thyroid cancer Miwa, Keisuke

34 S3 p. S1462
artikel
294 P18-5 Examination of the sequence of chemotherapy regimen in malignant pleural mesothelioma Negi, Yoshiki

34 S3 p. S1447
artikel
295 P47-1 FOLFOXIRI therapy with bevacizumab in metastatic colorectal cancer patient: Systematic review Theodeus Subroto, Dion Ravinder

34 S3 p. S1459
artikel
296 P34-6 Function of a HER2 VUS in colorectal cancer with APC mutations and its potential for HER2-targeted therapy Mitani, Yosuke

34 S3 p. S1455
artikel
297 P2-3 Gastric adenocarcinoma in adolescents and young adults: Patterns of care and survival in the Singapore Yeo, Dylan

34 S3 p. S1443
artikel
298 P34-2 Half dose pegfilgrastim for patients with breast cancer during chemotherapy: A case-series study Ikeda, Mako

34 S3 p. S1454
artikel
299 P64-4 HER2-directed therapies beyond progression in a patient with recurrent HER2-positive mucinous ovarian carcinoma Chan, Jack Junjie

34 S3 p. S1464
artikel
300 P12-2 Hypomethylating agent as first-line treatment for acute myeloid leukemia: Systematic review Jhoputri, Caroline Fricilia

34 S3 p. S1446
artikel
301 P12-1 Hypomethylating agent for acute myeloid leukemia, the efficacy and its effect towards mortality rate: Systematic review Tandokallo, Felicia

34 S3 p. S1446
artikel
302 P12-9 Ibrutinib combined with venetoclax treatment outcome in chronic lymphocytic leukemia: A systematic review Sugianto, Jeremy Octavian

34 S3 p. S1447
artikel
303 P37-7 Influence of cytosol calcium ion level on PDT efficacy in nasopharyngeal carcinoma cell line Wu, Ricky Wk

34 S3 p. S1455-S1456
artikel
304 P45-8 Iris metastasis as the initial presentation of male breast cancer: A case report Sainamthip, Panot

34 S3 p. S1459
artikel
305 P42-1 Malignant pleural mesothelioma first presenting as cutaneous metastases: A case report Bondoc Pineda, Angelica Marie

34 S3 p. S1457
artikel
306 P67-1 Metastatic patterns based on breast cancer subtypes: A study in a private Indonesian cancer hospital Tenggara, Jeffry Beta

34 S3 p. S1465
artikel
307 P36-3 Mixed learning improved learning outcome in clinical placement in radiation therapy education Cheung, Eva Y.W.

34 S3 p. S1455
artikel
308 P45-1 Neoadjuvant pembrolizumab for triple-negative breast cancer in 26-year-old woman: A South East Asian perspective Firsty, Naufal Nandita

34 S3 p. S1459
artikel
309 P49-1 Next-generation sequencing discordant ALK-rearrangement in non-small cell lung carcinoma with ovarian metastases Lay Tan, Charles Jeffrey

34 S3 p. S1460
artikel
310 P22-1 Nivolumab combination chemotherapy (NC) for HER2-negative, unresectable, advanced, or recurrent gastric cancer (AGC): A retrospective observational study Chikaishi, Wakana

34 S3 p. S1450
artikel
311 P47-7 Oral 5-FU+/-bevacizumab should be basically used for first-line chemotherapy for elderly colorectal cancerous patients Kobayashi, Kazuma

34 S3 p. S1460
artikel
312 P67-5 Our experience with immune checkpoint inhibitors in triple-negative breast cancer patients Nishio, Minako

34 S3 p. S1465
artikel
313 P24-3 Oxaliplatin desensitization therapy in patients with colorectal cancer Sato, Michiko

34 S3 p. S1450
artikel
314 P38-8 Phase 1/2 study of menin inhibitor DSP-5336 in acute leukemia with and without MLL rearrangement or NPM1 mutation Daver, Naval

34 S3 p. S1456
artikel
315 P40-2 Photodynamic therapy (PDT) on adult brain cancer glioblastoma multiforme (GBM): A systematic review Suntoro, Vanessa Angelica

34 S3 p. S1456
artikel
316 P37-6 Potential radiosensitizers for betel nuts-related head and neck squamous cell carcinoma in Taiwan Chen, Jo-Pai

34 S3 p. S1455
artikel
317 P31-8 Predictors of vulnerability to nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer Iede, Kiyotsugu

34 S3 p. S1453
artikel
318 P7-10 Primary mucoepidermoid carcinoma of the lung: A case report Techasatian, Tanwimon

34 S3 p. S1444
artikel
319 P41-6 Primary splenic angiosarcoma: A case report Tamtai, Amorn

34 S3 p. S1457
artikel
320 P25-3 Prognostic impact of concomitant antacids in EGFR-mutation-positive NSCLC: The Tokushukai REAl-world Data project (TREAD 01-S2) Uryu, Kiyoaki

34 S3 p. S1450
artikel
321 P10-2 Prognostic value of systemic inflammation in patients undergoing 1st-line chemotherapy for metastatic pancreatic cancer: Tokushukai REAl-world Data project Shimoyama, Rai

34 S3 p. S1445-S1446
artikel
322 P59-3 Psychiatric adverse effects of corticosteroid among cancer patients: Systematic review of case report, prospective study Sanjaya, Gisela Meydilin

34 S3 p. S1463
artikel
323 P21-2 RAD51D germline pathogenic variant in a young Filipino female with breast cancer: A case report Mendoza Lalusis, John Kelvin

34 S3 p. S1449
artikel
324 P43-1 Radiotherapy treatment in recurrent malignant proliferating trichilemmal tumour: A case report Salimin, Norhidayu

34 S3 p. S1457
artikel
325 P57-1 Real-world treatment outcomes of metastatic biliary tract cancer in Japan: Tokushukai REAl-world Data project; TREAD 04 Shimoyama, Rai

34 S3 p. S1462
artikel
326 P31-3 Real-world treatment outcomes of nal-IRI+5FU/LV in unresectable pancreatic cancer Kobayashi, Yuka

34 S3 p. S1453
artikel
327 P17-6 Report of the Cancer Salon at Jichi Medical University Hospital – the 8th report Yamamoto, Rie

34 S3 p. S1447
artikel
328 P40-3 Retrospective analysis of amrubicin therapy for advanced or recurrent neuroendocrine carcinoma in our facility Tsunoda, Akira

34 S3 p. S1456
artikel
329 P4-1 Retrospective analysis of ICIs treatment for the recurrence after CRT and durvalumab maintenance therapy Tsurumi, Kyoji

34 S3 p. S1444
artikel
330 P29-9 Retrospective study of comprehensive cancer genomic profile (CGP) testing for pancreatic cancer Nomura, Mitsutoshi

34 S3 p. S1452
artikel
331 P57-2 Retrospective study of second-line FOLFOX versus S1 for advanced biliary tract cancer Chida, Akihiko

34 S3 p. S1462
artikel
332 P37-5 Role of carotid glomus in the pathophysiology of postoperative hemorrhage in thyroid surgery: An experimental study Vabalayte, Kristina

34 S3 p. S1455
artikel
333 P54-2 Salmonella inhibition tumor metastasis by down-regulation of adrenoceptor beta 3 Huang, Yuting

34 S3 p. S1461
artikel
334 PS4-1 Atezolizumab following definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma Ooki, Akira

34 S3 p. S1381
artikel
335 PS3-2 Brexucabtagene autoleucel in relapsed/refractory mantle cell lymphoma (R/R MCL) in ZUMA-2: Durable responder analysis Munoz, Javier

34 S3 p. S1380
artikel
336 PS4-4 Early tumor shrinkage and depth of response with first-line panitumumab or bevacizumab and mFOLFOX treatment in PARADIGM Muro, Kei

34 S3 p. S1382
artikel
337 P27-9 Severe hypocalcemia due to osteoblastic metastases in a patient with metastatic prostate cancer: A case report Tamamritkul, Ratchanon

34 S3 p. S1451
artikel
338 PS1-2 First report of cohort 3 and mature survival data from the U31402-A-U102 study of HER3-DXd in EGFR-mutated NSCLC Hayashi, Hidetoshi

34 S3 p. S1379
artikel
339 PS3-5 Futibatinib for intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements: Japanese sub-analysis of FOENIX-CCA2 Morizane, Chigusa

34 S3 p. S1380
artikel
340 P55-1 Sonication improved the sensitivity of the MALDI-TOF MS for bacterial identification from direct urine samples Tik, Cheung Ka

34 S3 p. S1461
artikel
341 PS4-2 PD-1 blockade as curative intent therapy in mismatch repair deficient locally advanced rectal cancer Cercek, Andrea

34 S3 p. S1381
artikel
342 PS3-3 Pembrolizumab + chemoradiation therapy for locally advanced head and neck squamous cell carcinoma (HNSCC): KEYNOTE-412 Tahara, Makoto

34 S3 p. S1380
artikel
343 PS2-4 Phase 1/2 study of HER3-DXd in HER3-expressing metastatic breast cancer: Subgroup analysis by HER2 expression Iwata, Hiroji

34 S3 p. S1379
artikel
344 PS4-3 Survival analysis of m-FOLFOXIRI plus cetuximab vs. bevacizumab in RAS wild-type mCRC: The DEEPER trial (JACCRO CC-13) Tsuji, Akihito

34 S3 p. S1381
artikel
345 PS2-2 T-DXd vs TPC in patients with HER2-low unresectable and/or metastatic BC in Asian subgroup: Results of DESTINY-Breast04 Tsurutani, Junji

34 S3 p. S1379
artikel
346 PSY03-3 Claudin 18.2-targeted therapy for gastric and GEJ adenocarcinoma Shitara, Kohei

34 S3 p. S1355
artikel
347 PSY01-3 Financial toxicity of cancer treatment: From measurement to solutions Gyawali, Bishal

34 S3 p. S1355
artikel
348 P43-7 Synchronous invasive breast cancer and colon adenocarcinoma in a 57-year-old Filipino male Miro, John Michael

34 S3 p. S1458
artikel
349 PSY03-2 Perspective on emerging biomarker-driven therapies in gastric cancer, FGFR2 and beyond Wainberg, Zev A.

34 S3 p. S1355
artikel
350 PSY02-1 The power of patient engagement in drug development for rare cancers: Rationale for research co-creation, and mapping the current landscape Oliver, Kathy Rose

34 S3 p. S1355
artikel
351 P5-2 The addition of atezolizumab to chemotherapy in non-small cell lung cancer: Trial-based review and meta analysis Fitri, Nadya Keumala

34 S3 p. S1444
artikel
352 P2-1 The association between capsaicin consumption and risk of developing gastrointestinal cancer: Systematic review Sutanto, Riona

34 S3 p. S1443
artikel
353 P20-2 The potency of utilization ANLC lipid nanoparticle technology from grapes extract in the management of breast cancer Raditya Adi Kusuma, Pande Ketut

34 S3 p. S1449
artikel
354 P32-2 The role of early palliative care in increasing quality of life in patients with advanced cancer: A systematic review Argo, Teresa Mika

34 S3 p. S1454
artikel
355 P43-9 The treatment of Kaposi sarcoma: Chasing the progressive disease with the presentation of KICS Eiamprapaporn, Panuch

34 S3 p. S1458
artikel
356 P8-3 Time course of cancer genome panels at Osaka Red Cross Hospital Shimada, Takanobu

34 S3 p. S1444
artikel
357 P21-3 Trastuzumab deruxtecan-induced interstitial lung disease in a Filipino female patient with metastatic breast cancer Lim, Robyn Sy

34 S3 p. S1449
artikel
358 P2-2 Treatment outcome of gastric cancer in University Malaya Medical Centre (UMMC) Lim, Yi Way

34 S3 p. S1443
artikel
359 P54-1 Tribbles pseudokinase 3 contributes cancer stemness in head and neck cancer cells by supporting SOX2 and EGFR expression Chang, Wen-Wei

34 S3 p. S1461
artikel
360 P58-4 Two cases of sarcoma needing differentiation from hematopoietic tumor Aramaki, Hiroe

34 S3 p. S1463
artikel
361 P33-7 Two patients with DLBCL who developed aortitis following pegfilgrastim administration during chemoimmunotherapy Tamba, Mikako

34 S3 p. S1454
artikel
362 P8-10 WGS analysis of Erbb2-amplified cervical cancer with two simultaneous histologic types: Transdifferentiation hypothesis Ikushima, Hiroaki

34 S3 p. S1445
artikel
363 SJS-1 An overview of geriatric oncology in global clinical practice: A SIOG national representatives’ survey Mizutani, Tomonori

34 S3 p. S1352
artikel
364 SJS-3 Geriatric oncology in Australia Lane, Heather Patricia

34 S3 p. S1352
artikel
365 Society Pages
34 S3 p. vi-vii
artikel
366 SY23-1 Antibody-drug conjugates (ADCs) in treatment-resistant cancers: From basic to clinical applications Yonesaka, Kimio

34 S3 p. S1370
artikel
367 SY12-1 Assessment on clinical validity of PD-L1 assays in lung cancer Yatabe, Yasushi

34 S3 p. S1361
artikel
368 SY05-5 Clinical trials for advanced or recurrent cervical cancer Kim, Jae-Weon

34 S3 p. S1358
artikel
369 SY05-3 Controversies in the surgical treatment for local recurrent cervical cancer Takekuma, Munetaka

34 S3 p. S1358
artikel
370 SY05-2 Current controversies in systemic therapies for advanced or recurrent cervical cancer Chan, Jack Junjie

34 S3 p. S1358
artikel
371 SY13-2 Current evidences in the first-line treatment of metastatic non-clear cell renal cell carcinoma Inokuchi, Junichi

34 S3 p. S1362
artikel
372 SY05-1 Current management of recurrent/metastatic cervical cancer Tewari, Krishnansu Sujata

34 S3 p. S1358
artikel
373 SY19-2 Current progress in treatment strategy for recurrent or metastatic head and neck cancer Licitra, Lisa

34 S3 p. S1368
artikel
374 SY15-2 Current status and challenges of treatment for retroperitoneal sarcoma in Japan Honda, Kazunori

34 S3 p. S1365
artikel
375 SY14-5 Current status and future perspectives of genetic testing and therapy for hereditary tumors in pancreatic cancer Kawamoto, Yasuyuki

34 S3 p. S1364
artikel
376 SY17-3 Current status and future perspectives of treatment for advanced gastroenteropancreatic neuroendocrine neoplasms Fujimori, Nao

34 S3 p. S1366
artikel
377 SY22-3 Current status and prospects of novel molecular targeted therapy in AML Hosono, Naoko

34 S3 p. S1369
artikel
378 SY14-2 Current status of first-line treatment of metastatic pancreatic cancer Ozaka, Masato

34 S3 p. S1363
artikel
379 SY14-1 Current status of pancreatic cancer treatment in Europe Macarulla, Teresa

34 S3 p. S1363
artikel
380 SY23-3 Enfotulumab vedotin treatment, a novel ADC for urothelial carcinoma Uemura, Motohide

34 S3 p. S1370
artikel
381 SY17-1 Evidence and clinical practice of peptide receptor radionuclide therapy for unresectable neuroendocrine tumors Kobayashi, Noritoshi

34 S3 p. S1366
artikel
382 SY01-1 Future perspectives of molecular targets for GI cancer: Future of novel targets in advanced gastric cancer Rha, Sun Young

34 S3 p. S1356
artikel
383 SY28-1 Historical overview of cancer cachexia management Naito, Tateaki

34 S3 p. S1373
artikel
384 SY19-1 How to integrate immunotherapy into treatment strategy for locally advanced head and neck cancer Cohen, Ezra E.W.

34 S3 p. S1368
artikel
385 SY18-KL Incorporation of checkpoint inhibitors into first-line therapy for oesophageal cancer Chau, Ian

34 S3 p. S1367
artikel
386 SY14-3 Landscape and future perspectives of second-line chemotherapy for metastatic pancreatic cancer Imaoka, Hiroshi

34 S3 p. S1363
artikel
387 SY15-4 MASTER KEY Project Japan and MASTER KEY Asia; an Asian platform for rare cancers Okuma, Hitomi

34 S3 p. S1365
artikel
388 SY17-2 Medical treatment in pancreatic and gastrointestinal neuroendocrine neoplasm Hijioka, Susumu

34 S3 p. S1366
artikel
389 SY03-2 Molecular imaging unveils realistic features of T cell activation signaling via TCRs, costimulatory and coinhibitory receptors and CARs Yokosuka, Tadashi

34 S3 p. S1357
artikel
390 SY13-4 Novel combinations in progress in renal cancer Powles, Thomas

34 S3 p. S1362
artikel
391 SY06-1 Optimal therapy concepts in premenopausal patients with HR+ HER2- early breast cancer Harbeck, Nadia

34 S3 p. S1359
artikel
392 SY12-3 PD-L1 test for head and neck cancer and esophageal cancer Fujii, Satoshi

34 S3 p. S1361
artikel
393 SY12-2 PD-L1 testing in breast cancer Horii, Rie

34 S3 p. S1361
artikel
394 SY12-4 PD-L1 testing in gastric cancer Ushiku, Tetsuo

34 S3 p. S1361
artikel
395 SY01-2 Potential molecular targets for colorectal cancer based on recent genome-wide molecular classification Kikuchi, Osamu

34 S3 p. S1356
artikel
396 SY14-4 Recent treatment strategy for locally advanced pancreatic cancer Kanai, Masashi

34 S3 p. S1363
artikel
397 SY15-1 Reference centers and precision medicine trials in sarcoma Blay, Jean-Yves

34 S3 p. S1365
artikel
398 SY27-4 Statistical challenges when selecting primary endpoint(s) in perioperative RCTs in NSCLC Nomura, Shogo

34 S3 p. S1372
artikel
399 SY13-1 Strategies for favorable group of metastasis renal cell carcinoma Oki, Ryosuke

34 S3 p. S1362
artikel
400 SY24-1 The future of platform trials Dodd, Lori E.

34 S3 p. S1371
artikel
401 SY17-4 Therapeutic development for gastroenteropancreatic neuroendocrine neoplasms Chen, Ming-Huang

34 S3 p. S1366
artikel
402 SY13-3 The role of deferred cytoreductive nephrectomy in the era of immune checkpoint inhibitor Yaegashi, Hiroshi

34 S3 p. S1362
artikel
403 SY09-3 The role of fluoropyrimidines in HER2-negative early breast cancer Watanabe, Satomi

34 S3 p. S1360
artikel
404 SY06-4 The sensitivity to chemotherapy for breast cancer in premenopausal women: Differences from postmenopausal women and reasons for the differences Yoshinami, Tetsuhiro

34 S3 p. S1359
artikel
405 SY03-4 TIGIT blockade therapy from basic insights to clinics Zarour, Hassane M.

34 S3 p. S1357
artikel
406 SY22-5 Toward precision medicine in lymphoma: Challenges and opportunities Nakamura, Hirotaka

34 S3 p. S1369
artikel
407 SY06-2 Treatment and survivorship for premenopausal women with breast cancer Ono, Makiko

34 S3 p. S1359
artikel
408 Table of Contents
34 S3 p. v
artikel
409 Title Page
34 S3 p. iv
artikel
                             409 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland